AI Drug Developer TwoXAR Raises $10m In Series A

Californian biopharma, TwoXAR, which is using a computational platform to identify drug candidates, de-risks opportunities through preclinical studies, and progresses...

      

Related Stories

• Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product
• Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir
• Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales

 

Original Article: AI Drug Developer TwoXAR Raises $10m In Series A

More From BioPortfolio on "AI Drug Developer TwoXAR Raises $10m In Series A"